145 related articles for article (PubMed ID: 9126164)
1. Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease.
Bankiewicz KS; Leff SE; Nagy D; Jungles S; Rokovich J; Spratt K; Cohen L; Libonati M; Snyder RO; Mandel RJ
Exp Neurol; 1997 Mar; 144(1):147-56. PubMed ID: 9126164
[TBL] [Abstract][Full Text] [Related]
2. Application of ex vivo gene therapy in the treatment of Parkinson's disease.
Raymon HK; Thode S; Gage FH
Exp Neurol; 1997 Mar; 144(1):82-91. PubMed ID: 9126156
[TBL] [Abstract][Full Text] [Related]
3. Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation.
During MJ; Kaplitt MG; Stern MB; Eidelberg D
Hum Gene Ther; 2001 Aug; 12(12):1589-91. PubMed ID: 11529246
[TBL] [Abstract][Full Text] [Related]
4. Gene therapeutic strategies for neuroprotection: implications for Parkinson's disease.
Bowers WJ; Howard DF; Federoff HJ
Exp Neurol; 1997 Mar; 144(1):58-68. PubMed ID: 9126153
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic benefit of TH-engineered mesenchymal stem cells for Parkinson's disease.
Lu L; Zhao C; Liu Y; Sun X; Duan C; Ji M; Zhao H; Xu Q; Yang H
Brain Res Brain Res Protoc; 2005 May; 15(1):46-51. PubMed ID: 15878150
[TBL] [Abstract][Full Text] [Related]
6. [Gene therapy for Parkinson's disease: studies in animal models].
Muramatsu S
Rinsho Shinkeigaku; 2001 Dec; 41(12):1157-9. PubMed ID: 12235825
[TBL] [Abstract][Full Text] [Related]
7. Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease.
Herzog CD; Brown L; Gammon D; Kruegel B; Lin R; Wilson A; Bolton A; Printz M; Gasmi M; Bishop KM; Kordower JH; Bartus RT
Neurosurgery; 2009 Apr; 64(4):602-12; discussion 612-3. PubMed ID: 19349823
[TBL] [Abstract][Full Text] [Related]
8. Prospects for gene therapy in Parkinson's disease.
Freese A; Stern M; Kaplitt MG; O'Connor WM; Abbey MV; O'Connor MJ; During MJ
Mov Disord; 1996 Sep; 11(5):469-88. PubMed ID: 8866488
[TBL] [Abstract][Full Text] [Related]
9. In vivo gene delivery for development of mammalian models for Parkinson's disease.
Ulusoy A; Bjorklund T; Hermening S; Kirik D
Exp Neurol; 2008 Jan; 209(1):89-100. PubMed ID: 18028909
[TBL] [Abstract][Full Text] [Related]
10. Primary adult human astrocytes as an ex vivo vehicle for beta-glucuronidase delivery in the brain.
Serguera C; Sarkis C; Ridet JL; Colin P; Moullier P; Mallet J
Mol Ther; 2001 Jun; 3(6):875-81. PubMed ID: 11407901
[TBL] [Abstract][Full Text] [Related]
11. Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease.
Wang L; Muramatsu S; Lu Y; Ikeguchi K; Fujimoto K; Okada T; Mizukami H; Hanazono Y; Kume A; Urano F; Ichinose H; Nagatsu T; Nakano I; Ozawa K
Gene Ther; 2002 Mar; 9(6):381-9. PubMed ID: 11960314
[TBL] [Abstract][Full Text] [Related]
12. Delayed gene therapy of glial cell line-derived neurotrophic factor is efficacious in a rat model of Parkinson's disease.
Zheng JS; Tang LL; Zheng SS; Zhan RY; Zhou YQ; Goudreau J; Kaufman D; Chen AF
Brain Res Mol Brain Res; 2005 Mar; 134(1):155-61. PubMed ID: 15790539
[TBL] [Abstract][Full Text] [Related]
13. [Gene therapy and cell transplantation for Parkinson's disease].
Muramatsu S
Rinsho Shinkeigaku; 2005 Nov; 45(11):902-4. PubMed ID: 16447758
[TBL] [Abstract][Full Text] [Related]
14. [Gene therapy of tyrosine hydroxylase, aromatic L-amino acid decarboxylase, and GTP cyclohydrolase genes in rat model of Parkinson's disease].
Lu LL; Su Y; Duan CL; Zhao CL; Su YJ; Wu J; Zhao HY; Xu QY; Yang H
Zhonghua Yi Xue Za Zhi; 2004 Sep; 84(18):1528-32. PubMed ID: 15500713
[TBL] [Abstract][Full Text] [Related]
15. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector.
During MJ; Samulski RJ; Elsworth JD; Kaplitt MG; Leone P; Xiao X; Li J; Freese A; Taylor JR; Roth RH; Sladek JR; O'Malley KL; Redmond DE
Gene Ther; 1998 Jun; 5(6):820-7. PubMed ID: 9747462
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy in Parkinson's disease.
Eberhardt O; Schulz JB
Cell Tissue Res; 2004 Oct; 318(1):243-60. PubMed ID: 15322915
[TBL] [Abstract][Full Text] [Related]
17. [Cell and ex vivo gene therapy: advances in the treatment of central nervous system disorders].
Mejía-Toiber J; Castillo CG; Giordano M
Rev Neurol; 2009 Nov 1-15; 49(9):483-9. PubMed ID: 19859890
[TBL] [Abstract][Full Text] [Related]
18. Vectors--shuttle vehicles for gene therapy.
Wilson JM
Clin Exp Immunol; 1997 Jan; 107 Suppl 1():31-2. PubMed ID: 9020933
[TBL] [Abstract][Full Text] [Related]
19. An AAV-derived Apaf-1 dominant negative inhibitor prevents MPTP toxicity as antiapoptotic gene therapy for Parkinson's disease.
Mochizuki H; Hayakawa H; Migita M; Shibata M; Tanaka R; Suzuki A; Shimo-Nakanishi Y; Urabe T; Yamada M; Tamayose K; Shimada T; Miura M; Mizuno Y
Proc Natl Acad Sci U S A; 2001 Sep; 98(19):10918-23. PubMed ID: 11535810
[TBL] [Abstract][Full Text] [Related]
20. Progress in direct striatal delivery of L-dopa via gene therapy for treatment of Parkinson's disease using recombinant adeno-associated viral vectors.
Mandel RJ; Rendahl KG; Snyder RO; Leff SE
Exp Neurol; 1999 Sep; 159(1):47-64. PubMed ID: 10486174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
